Pharmacy chains activity analysis

Pharmacy chains activity analysis

Russian pharmaceuticals retail chain segment evaluation, both on the level of the state and in particular regions. Pharmacy chains development forecast

Forecasting

Product sales and separate market development forecast, based on unique mathematical models

Business and marketing plan development

Development of detailed business-plans, required to evaluate the reasonability of project start

Search of partners for contract production in Russia

Potential partners search and evaluation, based on their technical opportunities, appropriate experience, and reputation

Monitoring of import substitution

assessment of the main trends of import substitution policies and localization processes in the pharmaceutical market in Russia, the key beneficiaries and companies at risk

Database Update: Pharmaceutical Drug Production in Russia (June 2019)

Thursday, July 25, 2019

Between January and June 2019, Russia produced 186.8 bln RUB worth of pharmaceutical drugs (manufacturers’ dispatch prices, VAT included), which is monetary terms (rubles) 18.8% higher than that of the same period in 2018. In physical terms, the dynamics are only +1.3% in units and +1.2% in minimum dosage units (MDU). The total volume of production for the period is around 2.1 bln units or 35.2 bln MDUs.

In June 2019, the dynamics in monetary terms are +16.7%; higher dynamics have been registered only in February and April 2019. The dynamics in physical terms are reaching a historic low, though, with -8.6%, which is the worst dynamics over the past 14 months.

The dynamics of the OTC drug import in physical terms keep falling (-4.4%), while those of the Rx drug import keep rising (+10.2%). Six of the top 10 OTC drug manufacturers with the highest volume of production in physical terms have decreased dispatch volumes. The production dynamics in physical terms of Tatpharm and Uralbiofarm are -34% and -40%, respectively. Marathon Pharma and Pharmstandard have the highest dynamics in physical terms, +24% and +17%, respectively. For Marathon Pharma, Fluconazole and Rinorus contributed to the dynamics the most, with 3.8 and 2.1 times increases, respectively. Paracetamol and Citramon contributed to the dynamics of Pharmstandard (3.7 and 2.3 times increases, respectively). The dynamics of dispatch volumes of various anti-cold medicines have been quite high this year.

As for Rx drug production, the highest dynamics are demonstrated by the same manufacturers, including Solopharm (+47) and Ozon (+41%). However, these dynamics are not record-worthy, since Deko’s dynamics are as high as 91%. Cephalosporin antibiotics Cefotaxime and Ceftazidime contributed to the dynamics the most, with 7 and 5 times increases, respectively. Gedeon Richter is also worth mentioning. Verospiron contributed to the dynamics of +64% the most, partly because full cycle formulation of certain SKUs are localized in the Moscow region.

Read more about Russian pharmaceutical production (May 2019) here: http://www.rncph.com/news/21_06_2019

Dynamics of pharmaceutical drug production in Russia, including production of pharmaceuticals of foreign companies on owned or contract plants, in physical (units) and monetary terms (RUB, VAT included) (January 2018 – June 2019)

Share: